Skip to main content
OpenTrials
Completed

NCT Number: NCT00230893

Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tuscaloosa VA Medical Center

Tuscaloosa, Alabama, 35404, United States

About this study

This study is a retrospective electronic review of the VISN 7 Data Warehouse to determine what have been the emerging trends in prescriptions of atypical antipsychotic medications over the past seven years for the treatment of posttraumatic stress disorder (PTSD) in the VA

This study is a retrospective electronic review of patients of the VISN 7 Data Warehouse of patients with a diagnosis of PTSD treated with antipsychotics as monotherapy or adjunctive therapy at a VA Medical Center or VA clinic in VISN 7 (GA, SC, and AL). The data will be retrieved from a computerized list of patients treated in VA VISN 7 for PTSD from 1998-2005 and cross-referenced with the electronic pharmacy file for having received a prescription of an antipsychotic medication. No personal identifiers will be collected. The data will then be examined to determine what type of antipsychotics were prescribed and the dose and duration of the antipsychotics. In addition, demographics and clinical characteristics available through the Data Warehouse will be collected.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients, any race or ethnic origin at least 19 years of age.
  • Patients with a diagnosis of PTSD
  • Treated with an antipsychotic as a monotherapy or adjunctive therapy
  • Patient must have been seen at a VA medical center or clinic within VISN 7 during the study period.

Exclusion criteria

  • Patients not diagnosed with PTSD
  • Not treated with an antipsychotic as a monotherapy or adjunctive therapy
  • Patients outside of Network 7
  • Patients with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder

Sponsors and collaborators

Lead sponsor

Tuscaloosa Research & Education Advancement Corporation

Other

Collaborators

  • Janssen, LP

Registry information

Important dates

Study start
2005
Study completion
2005
First posted
Oct 3, 2005
Registry last updated
Sep 21, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.